We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Northwest Biotherapeutics Inc (QB) | USOTC:NWBO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.00594 | -1.27% | 0.46 | 0.451 | 0.4699 | 0.48 | 0.458 | 0.465 | 1,273,919 | 21:30:14 |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | |
Name
|
| |
Age
|
| |
Position
|
|
Linda F. Powers | | |
63
|
| | Class III Director, Chairperson, President and Chief Executive Officer | |
Dr. Alton L. Boynton | | |
74
|
| | Class I Director, Chief Scientific Officer | |
J. Cofer Black | | |
68
|
| | Class I Director | |
Dr. Navid Malik | | |
49
|
| | Class III Director | |
Jerry Jasinowski | | |
79
|
| | Class II Director | |
Name of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage
(1)
|
| ||||||
Officers and Directors | | | | ||||||||||
Alton L. Boynton, Ph.D.
(2)
|
| | | | 9,140,302 | | | | | | 1.7 % | | |
Marnix L. Bosch, Ph.D., M.B.A.
(3)
|
| | | | 7,335,688 | | | | | | 1.4 % | | |
Linda F. Powers
(4)
|
| | | | 137,235,503 | | | | | | 21.7 % | | |
Leslie J. Goldman
(5)
|
| | | | 20,972,862 | | | | | | 3.9 % | | |
Dr. Navid Malik
|
| | | | 7,695,547 | | | | | | 1.4 % | | |
Jerry Jasinowski
(6)
|
| | | | 6,172,237 | | | | | | 1.2 % | | |
J. Cofer Black
(7)
|
| | | | 1,454,019 | | | | | | * % | | |
All executive officers and directors as a group (7 persons)
|
| | | | 190,006,158 | | | | | | 27.8 % | | |
Significant Security Holder | | | | ||||||||||
Cognate BioServices, Inc.
(8)
4600 East Shelby Drive Suite 108, Memphis, TN |
| | | | 20,604,095 | | | | | | 3.9 % | | |
Name
|
| |
Age
|
| |
Position
|
|
Linda F. Powers | | |
63
|
| | Class III Director, Chairperson, President and Chief Executive Officer | |
Alton L. Boynton, Ph.D.
|
| |
74
|
| | Class I Director, Chief Scientific Officer | |
Leslie J. Goldman | | |
73
|
| | Senior Vice President, General Counsel | |
Marnix L. Bosch, Ph.D.
|
| |
60
|
| | Chief Technical Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Option
Awards ($) |
| |
Total
($) |
| |||||||||||||||
Linda F. Powers
Chairperson, President & Chief Executive Officer |
| | | | 2018 | | | | | $ | 502,000 | | | | | $ | — | | | | | $ | 6,698,000 | | | | | $ | 7,200,000 | | |
| | | 2017 | | | | | $ | 502,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 502,000 | | | ||
| | | 2016 | | | | | $ | 502,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 502,000 | | | ||
Alton L. Boynton, Ph.D.
Chief Scientific Officer and Secretary |
| | | | 2018 | | | | | $ | 325,000 | | | | | $ | — | | | | | $ | 1,485,000 | | | | | $ | 1,810,000 | | |
| | | 2017 | | | | | $ | 325,000 | | | | | $ | — | | | | | $ | 216,000 | | | | | $ | 541,000 | | | ||
| | | 2016 | | | | | $ | 325,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 325,000 | | | ||
Leslie J. Goldman
Senior Vice President, General Counsel |
| | | | 2018 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | 4,186,000 | | | | | $ | 4,561,000 | | |
| | | 2017 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 375,000 | | | ||
| | | 2016 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 375,000 | | | ||
Marnix L. Bosch, Ph.D.
Chief Technical Officer |
| | | | 2018 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | 260,000 | | | | | $ | 635,000 | | |
| | | 2017 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | 505,000 | | | | | $ | 880,000 | | | ||
| | | 2016 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 375,000 | | | ||
Other | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Susan Goldman*
|
| | | | 2018 | | | | | $ | 120,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 120,000 | | |
| | | 2017 | | | | | $ | 120,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 120,000 | | | ||
| | | 2016 | | | | | $ | 118,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 118,000 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date* |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) (1) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| |||||||||||||||||||||||||||
Linda F. Powers
Chief Executive Officer and President |
| | | | 33,234,783 (1) | | | | | | 5,965,217 | | | | | | — | | | | | | 0.23 | | | | | | 5/28/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Alton Boynton
Chief Scientific Officer and Secretary |
| | | | 3,119,347 (2) | | | | | | 283,588 | | | | | | — | | | | | | 0.25 | | | | | | 6/13/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 4,154,349 (2) | | | | | | 745,651 | | | | | | — | | | | | | 0.23 | | | | | | 5/28/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1,854,417 (2) | | | | | | 1,112,648 | | | | | | — | | | | | | 0.23 | | | | | | 8/31/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Leslie J. Goldman
Senior Vice President, General Counsel |
| | | | 20,771,736 (3) | | | | | | 3,728,264 | | | | | | — | | | | | | 0.23 | | | | | | 5/28/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Marnix L. Bosch
Chief Technical Officer |
| | | | 31,770 (4) | | | | | | 21,355 | | | | | | — | | | | | | 11.20 | | | | | | 6/23/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 15,625 (5) | | | | | | — | | | | | | — | | | | | | 8.80 | | | | | | 8/20/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 7,278,491 (6) | | | | | | 661,691 | | | | | | — | | | | | | 0.25 | | | | | | 6/13/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Year
|
| |
Fees Earned or
Paid in Cash ($) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Dr. Navid Malik
|
| | | | 2018 | | | | | $ | 150,000 | | | | | $ | — | | | | | $ | 150,000 | | |
Jerry Jasinowski
|
| | | | 2018 | | | | | $ | 150,000 | | | | | $ | — | | | | | $ | 150,000 | | |
J. Cofer Black
|
| | | | 2018 | | | | | $ | 150,000 | | | | | $ | — | | | | | $ | 150,000 | | |
1 Year Northwest Biotherapeutics (QB) Chart |
1 Month Northwest Biotherapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions